School's Out But This Stock Is In

Monday, July 22, 2013
	Refer a Friend  |  Visit Our Website  |  Unsubscribe   Advertisers
		School's Out But This Stock Is In   by Rob Goldman     I had the opportunity to meet with a successful microcap and small-cap investor. We shared stories about wine, women, song and stocks.  About halfway through the conversation, the gentleman (and believe me, I use that term loosely) admitted that in his early years of investing, gains were hard to come by while losses dominated his portfolio.    Yet today, he is a very wealthy man as a direct result of his ability to pick stocks.   I asked him, "What changed?"   He replied by telling me that it finally hit him one day that he misunderstood pundits' guidance. And once he changed his approach, he bought the right stocks at the right time and learned not to be greedy as stocks move higher. Moreover, he set a limit on losses that had a major impact as well.    To read more click here >> or visit http://www.thestockjunction.com   VISIT OUR SPONSOR   Avoid The Collapse - SELL ALERT!   Millions of Americans own shares of three big name companies in their portfolios.  We think it's "Dead Money."  These Stocks are about to collapse... and time's running out for you to sidestep big losses!   If you don't read this special alert, it could cost you tens of thousands of dollars! CLICK HERE     Why This Pure-Play Breast Health Stock Could Triple   by Rob Goldman     In the most recent edition of The Stock Junction, I noted how I discovered a great opportunity by typing the wrong symbol on my laptop.  In contrast, the genesis behind today's profiled stock was no accident.    With a number of stocks reaching new highs in recent weeks, we sought to unearth stocks that offer major upside but have not yet begun their ascent.  As part of our due diligence, we believe we have discovered a medical diagnostic stock that has just reached the key commercialization inflection point, and appears primed to have a tremendous second half of 2013.  Moreover, the technology - which has more patents associated with it than we ever remember seeing before - looks like it could become the most ubiquitous female diagnostic breast cancer screening tool during the next 7-10 years.    Atossa Genetics, Inc. (NASDAQ: ATOS - $4.87) is a healthcare diagnostic firm focused exclusively on breast health. This pure play on breast cancer and wellness offers patented products and laboratory services that address breast cancer risk assessment and prevention. The multi-billion dollar market targets up to 110 million women aged 18-73 in the U.S. alone.   To read more click here >> or visit http://www.thestockjunction.com

		Disclaimer & Important Information TheStockJunction.com is owned and published by Champlain Media, LLC of Richmond, Vermont. Champlain Media is neither a registered investment adviser nor a broker/dealer. Readers are advised that this electronic publication is issued solely for information purposes and should not to be construed as an offer to sell or the solicitation of an offer to buy any security. We encourage you to review our full Disclaimer and Disclosure policies. To view our Disclaimer Policy, please click here. To view our Disclosure Policy, please click here. You are subscribed with the following email address: ignoble.experiment@arconati.us To unsubscribe from this newsletter, please click here. Interested in advertising with us? CLICK HERE!   Copyright (c) 2013 The Stock Junction | Privacy Policy c/o Champlain Media 65 Railroad Street Richmond, VT 05477 PO Box 790